FDA Approves Pembrolizumab and Berahyaluronidase alfa-pmph for Subcutaneous Injection By Ogkologos - October 2, 2025 213 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the Study MK-3475A-D77 Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Pancancer Activity of Dabrafenib Plus Trametinib in Patients with BRAFV600E-Mutated Rare... April 24, 2023 Breast Cancer Survivor Given 12 Months to Live After Left Side... April 2, 2021 Leading Change in Cancer Clinical Research, Because Our Patients Can’t Wait May 31, 2024 Pembrolizumab Combined with Chemoradiotherapy Improves PFS in Women with Newly Diagnosed,... March 27, 2024 Load more HOT NEWS Decorated Veteran Learns She Has Triple-Positive Breast Cancer While Pregnant with... New on NCI’s Websites for September 2020 Help seeking: Why isn’t it as simple as it might sound? EMA Recommends Extension of Therapeutic Indications for Durvalumab and Adopts a...
